Boston Scientific Corp. (BSX) recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent in the U.S. and Europe. The new product is used for the treatment of malignant esophageal strictures (obstructions) caused by tumors in patients with resectable or non-resectable esophageal cancer.

With the new approval, Boston’s complete portfolio of WallFlex Stent family of self-expanding metal stents is now available in the U.S. , Europe and other international markets. The company had earlier received approval for marketing the WallFlex Partially Covered Esophageal Stent in U.S. and Europe in 2008.

The WallFlex Fully and Partially Covered Stents prevent tumor ingrowth by using a proprietary Permalume silicone covering. This also reduces the impaction of food. It is seen that patients suffering from esophageal cancer may have difficulties in swallowing, even while consuming liquids. The WallFlex Esophageal Stent prevents this by re-establishing patency (openness) of the esophagus. This in turn makes life easier for patients.

We think that the unique features of the WallFlex Fully Covered Stents are likely to make them widely acceptable amongst surgeons. This will boost demand for these stents which will increase the company’s top-line.

Boston Scientific is a manufacturer of medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors include Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).

Zacks Investment Research

1. (BSX) Boston Scientific Corporation Surpasses EstimatesBoston Scientific Corporation (BSX) yesterday reported financial results for the third quarter of fiscal 2009...
2. (BSX) Boston Scientific Readies for Clinical TrialBoston Scientific Corporation (BSX) announced its first patient enrollment for the MADIT-RIT clinical trial. The...
3. (BSX) Boston Scientific Corporation Settles Patent Infringement With Johnson & JohnsonBoston Scientific Corporation (BSX) yesterday announced that it will settle fourteen patent infringement lawsuits against...
4. (BSX) Positive SYNTAX for Boston Scientific StentBoston Scientific Corporation (BSX) recently came out with its two-year SYNTAX clinical data that do...
5. (BSX) Boston Scientific Registers Positive Results From MADIT TrialBSX: Positive Results from MADIT Trial Boston Scientific Corporation (BSX) announced positive final results from...
6. (BSX) Boston Scientific is Ready For MADIT ResultsBoston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which...

Search Posts by Tag: Abbott Laboratories | ABT | Boston Scientific Corporation | BSX | JNJ | Johnson & Johnson | MDT | Medtronic Inc | St. Jude Medical Inc | STJ | Healthcare

RSS Feeds by Tag: Abbott Laboratories | ABT | Boston Scientific Corporation | BSX | JNJ | Johnson & Johnson | MDT | Medtronic Inc | St. Jude Medical Inc | STJ | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author